Denali Therapeutics (DNLI) Current Deferred Revenue (2017 - 2023)
Denali Therapeutics (DNLI) posted quarterly Current Deferred Revenue of $290.1 million for Q4 2022, up 939.06% year-over-year from $27.9 million in Q4 2021, and up 1261000.0% quarter-over-quarter from $23000.0 in Q3 2022.
Denali Therapeutics (DNLI) Current Deferred Revenue (2017 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has reported Current Deferred Revenue for 6 consecutive years, with $290.1 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Current Deferred Revenue rose 939.06% year-over-year to $290.1 million; the TTM figure through Dec 2022 stood at $290.1 million (up 939.06% YoY), while the FY2022 annual figure was $290.1 million, up 939.06% from the prior year.
- Current Deferred Revenue grew to $290.1 million in Q4 2022 per DNLI's latest filing, from $23000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $290.1 million in Q4 2022 and bottomed at $23000.0 in Q3 2022.
- Historically, Current Deferred Revenue has averaged $31.2 million across 5 years, with a median of $18.5 million in 2019.
- Annual changes were most pronounced in 2019 — Current Deferred Revenue jumped 2548.51% — and 2022, when it plunged 98.26%.
- Denali Therapeutics' Current Deferred Revenue stood at $11.4 million in 2018, then soared by 63.99% to $18.7 million in 2019, then increased by 6.27% to $19.9 million in 2020, then surged by 40.18% to $27.9 million in 2021, then soared by 939.06% to $290.1 million in 2022.
- Business Quant data shows DNLI's Current Deferred Revenue at $290.1 million in Q4 2022, $23000.0 in Q3 2022, and $27.9 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.30 Mn |
| Mar 31, 2023 | 290.40 Mn |
| Dec 31, 2022 | 290.05 Mn |
| Sep 30, 2022 | 23,000.00 |
| Dec 31, 2021 | 27.92 Mn |
| Sep 30, 2021 | 1.32 Mn |
| Jun 30, 2021 | 5.76 Mn |
| Mar 31, 2021 | 12.89 Mn |
| Dec 31, 2020 | 19.91 Mn |
| Sep 30, 2020 | 28.02 Mn |
| Jun 30, 2020 | 34.13 Mn |
| Mar 31, 2020 | 24.67 Mn |
| Dec 31, 2019 | 18.74 Mn |
| Sep 30, 2019 | 18.19 Mn |
| Jun 30, 2019 | 22.60 Mn |
| Mar 31, 2019 | 23.15 Mn |
| Dec 31, 2018 | 11.43 Mn |
| Sep 30, 2018 | 12.66 Mn |
| Jun 30, 2018 | 8.72 Mn |
| Mar 31, 2018 | 874,000.00 |